Register for information and updates

Please fill in your contact information below:

*Required Fields

There was a problem with your submission. Errors have been highlighted below.

Thank you for your interest in INCRELEX

Yes, I would like to be contacted by the INCRELEX Nurse Specialist Team.

Name

First

Last

What is your specialty?

Practice/Hospital/University name

Address

Street Address

Address Line 2

City

County / State / Region

ZIP / Postal Code

Country

Would you also like to be contacted by an Account Manager? *

Consent *

By entering this information, I confirm that I am a healthcare professional at least 18 years of age, and that I agree to be contacted. I understand that my phone number and/or email address will be used for this purpose only and that my contact information will not be used or shared with any third parties for marketing purposes. I also consent to receive autodialed and prerecorded/artificial voice marketing calls from Ipsen Biopharmaceuticals, Inc. and its agents or affiliates, and on its and their behalf, at the phone number that I provide. I understand that my consent is not required or a condition of purchasing any products and services. I understand that to the extent that I have opted-out of communications via the American Medical Association Physician Data Restriction Program, my consent provided here will prevail with respect to the communications described above. We are collecting personal information in order to fulfill your personal request. Please see Ipsen's Privacy Policy here.

Important Safety Information and Indication

Contraindications

Hypersensitivity to mecasermin (rhIGF-1), any of the inactive ingredients in INCRELEX^®, or who have experienced a severe hypersensitivity to INCRELEX^®. Allergic reactions have been reported, including anaphylaxis requiring hospitalization.
Intravenous Administration.
Closed Epiphyses.
Malignant Neoplasia in pediatric patients with malignant neoplasia or a history of malignancy.

Warnings and Precautions

Hypoglycemia: INCRELEX^® should be administered 20 minutes before or after a meal or snack and should not be administered when the meal or snack is omitted. Glucose monitoring and INCRELEX^® dose titration are recommended until a well-tolerated dose is established and as medically indicated.
Intracranial Hypertension: Funduscopic examination is recommended at the initiation of and periodically during the course of therapy.
Lymphoid Tissue Hypertrophy: Patients should have periodic examinations to rule out potential complications.
Slipped Capital Femoral Epiphysis: Carefully evaluate any pediatric patient with the onset of a limp or hip/knee pain during INCRELEX^® therapy.
Progression of Scoliosis: Patients with a history of scoliosis, treated with INCRELEX^®, should be monitored.
Malignant Neoplasia: There have been postmarketing reports of malignant neoplasia in pediatric patients who received treatment with INCRELEX^®. The tumors were observed more frequently in patients who received INCRELEX^® at higher than recommended doses or at doses that produced serum IGF-1 levels above the normal reference ranges for age and sex. Monitor all patients receiving INCRELEX^® carefully for development of neoplasms. If malignant neoplasia develops, discontinue INCRELEX^® treatment.
Risk of Serious Adverse Reactions in Infants due to Benzyl Alcohol Preserved Solution: Serious and fatal adverse reactions including “gasping syndrome” can occur in neonates and infants treated with benzyl alcohol-preserved drugs. Use of INCRELEX^® in infants is not recommended.

Adverse Reactions

Common adverse reactions include hypoglycemia, local and systemic hypersensitivity, and tonsillar hypertrophy.

Indication

INCRELEX^® (mecasermin) is indicated for the treatment of growth failure in pediatric patients aged 2 years and older with severe primary IGF-1 deficiency* (IGFD), or with hormone (GH) gene deletion who have developed neutralizing antibodies to GH.¹

Limitations of use: INCRELEX^® is not a substitute to GH for approved GH indications. INCRELEX^® is not indicated for use in patients with secondary forms of IGFD, such as GH deficiency, malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.¹

*Severe primary IGF-1 deficiency (IGFD) is defined by height standard deviation score ≤ -3.0 and basal IGF-1 standard deviation score ≤ -3.0 and normal or elevated GH.